title: Cost and effectiveness of screening methods for abnormal fasting plasma glucose among Thai adults participating in the annual health check-up at King Chulalongkorn Memorial Hospital.
abstract: BACKGROUND
  In Thailand, type 2 diabetes screening was implementing at national level by the Ministry of Public Health (MOPH) recommendation but screening methods have not been fully evaluated Objective: To compare the performance, cost, and cost-effectiveness offour screening methods in identifying individuals with abnormal fasting plasma glucose among Thai adults participating in the annual health check-up at King Chulalongkorn Memorial Hospital.
  
  
  METHODS
  Individuals aged 35 to 60 years old with no known abnormal fasting plasma glucose (2977 persons) were recruited All subjects completed a set of screening questionnaires and were tested for venous fasting plasma glucose (FPG). One-time screening performance and costs were analyzed.
  
  
  RESULTS
  Sensitivities of all screening methods ranged from 71 to 92%, while specificities were between 31 and 57%. The total costs ofscreening per one newly detected case were 59.12 to 69.62 U.S. dollars (2022 to 2381 bahts). Compared to the universal FPG test, all screening methods using questionnaires were relatively more cost-effective. Their relative cost-effectiveness was, however, not obviously different.
  
  
  CONCLUSIONS
  Other factors should also be considered in selecting type 2 diabetes screening method for specific population in Thailand
authors.affiliation: College of Public Health Sciences, Chulalongkorn University Bangkok, Thailand.
authors.forename: Nipa
authors.initials: N
authors.lastname: Srichang
authors.forename: Wiroj
authors.initials: W
authors.lastname: Jiamjarasrangsi
authors.forename: Wichai
authors.initials: W
authors.lastname: Aekplakorn
authors.forename: Siripen
authors.initials: S
authors.lastname: Supakankunti
mesh_terms: D000328:Adult; D044466:Asian People / Q000706:statistics & numerical data; D001786:Blood Glucose / Q000032:analysis*; D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000175:diagnosis* / Q000191:economics / Q000453:epidemiology; D005260:Female; D005951:Glucose Tolerance Test; D006785:Hospitals, University; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000453:epidemiology; D008297:Male; D008403:Mass Screening / Q000191:economics* / Q000379:methods*; D008875:Middle Aged; D015995:Prevalence; D012680:Sensitivity and Specificity; D011795:Surveys and Questionnaires; D013785:Thailand / Q000453:epidemiology
chemical_list: D001786:Blood Glucose